Home >> Tag Archives: 23andMe—

Tag Archives: 23andMe—

FDA clears first DTC genetic test on cancer risk

March 16, 2018—23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk. The authorization allows 23andMe to provide customers, without a prescription, information on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in people of Ashkenazi Jewish descent. These three mutations, however, are not the most common BRCA1/BRCA2 mutations in the general population. ...

Read More »

23andMe, partners launch Nevada population study

Sept. 28, 2016—Nevada-based Renown Health and the Desert Research Institute are collaborating with 23andMe to launch a statewide population health study. The project will combine health, population, and genetic information with environmental data and return 23andMe genetic results to study participants. Funded by the Renown Health Foundation and Nevada’s Knowledge Fund, this pilot study will offer community members the opportunity ...

Read More »

23andMe offers genotyping services to researchers

Aug. 31, 2016—23andMe has launched a Genotyping Services for Research platform, designed to provide scientists with an end-to-end service to incorporate genetic information into their studies. “GSR simplifies the genotyping process and allows any researcher with an IRB-approved study to incorporate genetics into their research, regardless of their own genetics expertise,” Ruby Gadelrab, 23andMe’s vice president of commercial marketing, said ...

Read More »

23andMe offers new version of genome service

Oct. 26, 2015—23andMe has launched a new version of its personal genome service. Following two years of work with the FDA, extensive user comprehension testing and a complete redesign, 23andMe’s offering includes carrier status, wellness, trait, and ancestry reports. The announcement follows an October 2013 FDA order that 23andMe stop marketing the previous version of its direct-to-consumer genomics service. “We’ve ...

Read More »